pRAPacc1 and (B) pRAPacc2 used for stable insertion to generate acceptor cell lines and providing a FRT-sequence 1 for consecutive site-specific recombination. (C) pRAPtar-1c and (D) pRAPtar-1i used for construction of isogenic single recombinants with constitutive and dox-inducible overexpression, respectively. The FRT-site is used for Flp-recombinase mediated recombination into the pRAPacc1 or pRAPacc2 vector inserted into the host cell`s genome. Correct recombination puts the promoter/start codon-deficient hygromycin resistance gene (Hyg R ) under the control of the promoter/start codon that was previously driving EGFP expression. Simultaneously, a lox71-sequence 2 for Cre-mediated recombination of a second plasmid is provided, which is linked to the simian virus 40 promoter (P SV40). AttR1 and attR2 flank a GATEWAY system-compatible cassette that would be exchanged for the sequence of interest via in vitro recombination. Anti-repressor elements (AR) are included to suppress promoter silencing after insertion into the genome 3 . Finally, pRAPtar-1i carries a Tet-repressor (TetR) in cis, so that the same acceptor cell line can be used to derive isogenic single recombinants with either constitutive or inducible expression in a single step. (E) pRAPtar-2c and (F) pRAPtar-2i for construction of isogenic double recombinant cells (IDRs) with constitutive or inducible expression, respectively, of a second sequence. The lox66-site is cloned in front of a puromycin resistance gene (Puro R ), which, after Cre-mediated recombination, is placed under the control of the P SV40 of the pRAPtar-1 plasmid. A phiC31 attP site 4 linked to another P SV40 would then be available for insertion of a third plasmid via site-specific recombination. emerges from the inserted pRAPacc1/2 plasmid prior to site-specific recombination. After successful recombination EGFP expression is eliminated. Inducible expression in isogenic single recombinants (ISRs) was evaluated with the HcRed reporter gene shuttled into the pRAPtar-1i vector in the absence of doxycycline (dox-) and 48 hours after induction with 50 ng/ml doxycycline (dox+). For A549-ACLX12 the constitutive pRAPtar-1c vector with HcRed was additionally evaluated in flow cytometry. (B) Quantitatively tunable induction of gene expression was analyzed and confirmed for one ACL clone per cancer cell line using HcRed in pRAPtar-1i and applying the different doxycycline concentrations depicted in ng/ml at the respective profile. The green curve marked as ACL is HcRed fluorescence of the acceptor cell line prior to recombination, serving as negative control.
